Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-624-3 | CAS number: 108-87-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 Sep 2010 - 01 Dec 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Methylcyclohexane
- EC Number:
- 203-624-3
- EC Name:
- Methylcyclohexane
- Cas Number:
- 108-87-2
- Molecular formula:
- C7H14
- IUPAC Name:
- methylcyclohexane
- Details on test material:
- - Name of test material (as cited in study report): Methylcyclohexane
- Substance type: pure substance
- Physical state: clear colourless liquid with characteristic odour
- Analytical purity: 99.9%
- Lot/batch No.: KWH4629
- Stability under test conditions: Verified after study completion
- Storage condition of test material: Temperature: 22 - 25°C, Humidity: 40.8 - 67%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Japan, Inc., Yokohama, Japan
- Age at study initiation: 10 wks
- Weight at study initiation: 319 - 378 g (males); 246 - 276 g (females)
- Housing: individual in stainless steel cages
- Diet: CRF-1, pelleted, ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 17 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.0 - 23.8
- Humidity (%): 41.4 - 63.3
- Air changes (per hr): 12
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 22 Sep 2010 To: 01 Dec 2010
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Dosing solutions were prepared more than once a week. Concentration of stock solution was 200 mg/mL and stored at 4 °C in a refrigerator. The stock solution was diluted with corn oil to achieve the concentration of the dosing solutions.
VEHICLE
- Concentration in vehicle: 12.5, 50 and 200 mg/mL
- Amount of vehicle: 5 mL/kg bw
- Lot/batch no.: V8N8411 and V03H3633 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of the dosing solutions was verified by GC. The results were 94.2 - 99.4% of target concentration.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily, 7 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
62.5, 250 and 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 6 males, 5 females per dose (main study)
6 males per dose (satellite control and treatment groups)
5 females per dose (satellite control and high-dose groups) - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: dose levels were based on the results of a foregoing range finding study, in which animals were orally exposed to 0, 200, 500 and 1000 mg/kg bw/day for 14 days. Decrease in weight of thymus and increase in liver weight in both sexes, increase in platelet, decrease in leucocytes, increase in total protein and total cholesterol in males were observed at 1000 mg/kg bw/day. Therefore, 62.5, 250 and 1000 were selected as the dose levels for the main study.
- Post-exposure recovery period in satellite groups: 14 days
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice a day during administration period, daily during recovery period, and once before necropsy
DETAILED CLINICAL OBSERVATIONS: Yes (including FOB)
- Time schedule: Day 0, 7, 14, 21 and 27
BODY WEIGHT: Yes
- Time schedule for examinations: twice a week (Day 1, 4, 8, 11, 15, 18, 22, 25 and 28 during administration period, Day 1, 4, 8, 11, 14 and 15 during recovery period)
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
WATER CONSUMPTION: Yes
- Time schedule for examinations:
Males: on Day 2, 5, 9 and 12 of administration, on Day 2, 5, 9 and 12 of recovery
Females: on Day 2, 5, 9, 12, 16, 19, 23 and 26 of administration, on Day 2, 5, 9 and 12 of recovery
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on the day after last administration or Day 15 of recovery period
- Anaesthetic used for blood collection: Yes (Pentobarbital-Na)
- Animals fasted: Yes
- How many animals: all
- Parameters examined: RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, Platelets, Reticulocytes, PT, APTT, Fibrinogen, WBC, Differential leukocytes: Lymphocytes, Neutrophils, Eosinophils, Basophils, Monocytes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on the day after last administration or Day 15 of recovery period
- Animals fasted: Yes
- How many animals: all
- Parameters examined: AST, ALT, ALP, gamma-GTP, T-potein, Albumin, A/G, T-bilirubin, Urea nitrogen, Creatinine, Glucose, T-cholesterol, Triglycerides, Na, K, Cl, Ca, Inorganic-P, Fe
URINALYSIS: Yes
- Time schedule for collection of urine: before administration on Day 22 in males, Day 24 in females, Day 12 of recovery period
- Metabolism cages used for collection of urine: Yes
- Animals fasted: No
- Parameters examined: Color, pH, Protein, Glucose, Ketone body, Bilirubin, Occult blood, Urobilinogen, Urinary sediments, Epithelial cells, Erythrocytes, Leukocytes, Casts, Crystals
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: at the end of the administration period
- Dose groups that were examined: all
- Battery of functions tested: sensory activity / grip strength / motor activity
HORMONE CONCENTRATION
- Time schedule for collection of blood: on day after last administration or day 15 of recovery period
- Animals fasted: Yes
- How many animals: all
- Parameters examined: T3, T4 and TSH - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes.
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera.
- Organ weight: Brain, pituitary, salivary glands, thyroids, thymus, heart, liver, spleen, kidneys, adrenals, testes, epididymides, ventral prostate, seminal vesicles, ovaries and uterus.
HISTOPATHOLOGY: Yes.
- Tissues examined: Heart, lung, trachea, liver, pancreas, sublingual gland, oesophagus, stomach, duodenum, jejunum, ileum, Payer's patch, caecum, colon, rectum, thymus, spleen, mandibular lymph node, mesenteric lymph node, kidney, urinary bladder, testis, epididymis, ventral prostate, seminal vesicle, coagulating gland, pituitary, adrenal, thyroid, parathyroid, cerebrum, cerebellum, pons, spinal cord, sciatic nerve, eyeball, harderian gland, sternal bone, gemoral bone, sternal bone marrow, femoral bone marrow, muscle (rectus femoris), mammary gland, ovary, uterus, vagina and mammary gland. - Statistics:
- Differences in body weight, food consumption, water consumtion, clinical observation (frequency of urination, defecation rearing and grooming), grip strength, spontaneous motor activity, volume of urine, specific gravity of urine, hematological findings, clinical biochemistry findings, blood concetration of hormone (T3, T4 and TSH) and organ weight were tested by Bartlett's test. In case of homogeneity of variance or heteroscedasticity, Dunnett's test or Steel's test was performed between administration groups and control groups, respectively.
For differences in body weight, food consumption, water consumption, volume of urine, specific gravity of urine, hematological findings, clinical biochemistry findings and organ weight of female during recovery period, F test was applied. In case of homogeneity of variance or heteroscedasticity, Student' t-test or Aspin-Welch t-test was performed between administration groups and control groups, respectively.
For differences in clinical observation (except for frequency of urination, defecation, rearing and grooming) and sensory reactivity, Steel test was applied.
For differences in histopathological findings, Steel test was performed. In case of significant difference, Cochran-Armitage test was applied to test dose response relationship.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw/day (male and female): transient salivation following dosing
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 1000 mg/kg bw/day (male and female): transient salivation following dosing
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 250 and 1000 mg/kg bw/day (recovery males): slight decrease in MCHC and WBC; 1000 mg/kg bw/day (females): increase in reticulocytes and monocytes
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- all groups (males): increase in total cholesterol, reversible except for high-dose group; 250 mg/kg bw/day (males): slight decrease in Cl, reversible; 1000 mg/kg bw/day (males): increase in ALT (non-reversible), gamma-GT (reversible)
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- 1000 mg/kg bw/day (males): non-adverse transient increase in urine volume
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- 250 mg/kg bw/day (males): increased liver weight, reversible; 1000 mg/kg bw/day (males): increased liver and kidney weights, reversible; 1000 mg/kg bw/day (females): increased liver, kidney, adrenals and uterus weights, reversible except for liver weight
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- 250 and 1000 mg/kg bw/day (males): slight bilateral hyaline droplet in the renal tubule, reversible
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
11 males in the 1000 mg/kg bw/day group showed transient salivation. No abnormalities and no mortalities were observed in other groups during administration and recovery periods.
9 females in the 1000 mg/kg bw/day group showed transient salivation. No abnormalities and no mortalities were observed in other groups both during administration period and recovery period.
BODY WEIGHT AND FOOD CONSUMPTION
No changes were found between control and administration groups in both sexes during the study period.
WATER CONSUMPTION
Males in the 62.5 mg/kg bw/day group showed a significant decrease in water consumption on Day 12 of administration. However, no changes were found in higher dose groups. These changes were not regarded as relevant toxicological effects. On the other hand, no changes were observed in females during administration and recovery period.
DETAILED CLINICAL OBSERVATION
6 males, 4 males and 3 males showed slight salivation on Day 14, 21 and 27 of administration, respectively. Frequency of defecation was increased at dose of 62.5 and 1000 mg/kg bw/day on Day 14 of administration. However, these changes were not considered toxicologically relevant since observations were transient. Frequency of defecation was significantly increased at 62.5 mg/kg bw/day on Day 21 of administration. However, this was not considered a toxicological effect, since the change was not found in higher dose groups.
One female at 1000/kg bw/day showed slight salivation on Day 14 and 21 of administration. A significant increase in frequency of defecation was observed on Day 21 of administration in the 250 mg/kg bw/day group. This change was not due to the test item, since there was no dose-response relationship.
SENSORY REACTIVITY, GRIP STRENGTH, SPONTANEOUS MOTOR ACTIVITY
No changes were found in both sexes during the study period.
URINALYSIS
A significant increase in urine volume was observed at 1000 mg/kg bw/day in males towards the end of the administration period on Day 22. This change was not considered toxicologically relevant, since the urine volume in the control group (8.7 mL) was apparently less than usual. Thus, the urine volume of the control group was 13.4 mL after the recovery period.
No changes were found in females.
HEMATOLOGICAL FINDINGS
No changes were found in males after the administration period. After the recovery period, MCHC values were slightly (ca. 1.5%) but significantly decreased in males dosed 250 and 1000 mg/kg bw/day. WBC values were decreased in all administration groups, changes being significant in males at 62.5 and 1000 mg/kg bw/day. The toxicological relevance of this finding is questionable since such a tendency was not observed at the end of the administration period and the corresponding control value (68.3E02/µL) was clearly lower than the one after the recovery period (79.0E02/µL). Basophils seemed to be also significantly lower but this change was within the range of historical data of the test facility. Therefore, it was not considered to be test item-related.
A significant increase in reticulocytes and monocytes was observed in females of the 1000 mg/kg bw/day group after the administration period. This effect was not seen after the recovery period.
CLINICAL BIOCHEMISTRY FINDINGS
In comparison with the control group, total cholesterol was significantly increased in males of all treated groups after the administration period without clear dose-response relationship. ALT, gamma-GT, total protein and Ca values were significantly increased, and Cl significantly decreased, in males at 1000 mg/kg bw/day after the administration period. Cl values were slightly but significantly decreased at 250 mg/kg bw/day. ALT and total cholesterol were still significantly increased in males of the satellite recovery group dosed 1000 mg/kg bw/day. Glucose was significantly decreased in males of the satellite recovery group dosed 250 mg/kg bw/day. This last change was not regarded as toxicologically relevant since no dose-response relationship was observed and no significant changes were seen after the administration period.
Glucose was significantly decreased in females of the 1000 mg/kg bw/day group after the administration period. No changes were found in females of the satellite recovery groups.
HORMONE CONCENTRATION
No differences were found between control and administration groups after the administration period.
ORGAN WEIGHTS
In males at the dose level of 1000 mg/kg bw/day, absolute and relative weight of liver and kidney were significantly increased in comparison with the control group after the administration period. Relative liver weight was slightly (by 8.5%) but significantly increased in males dosed 250 mg/kg bw/day after the administration period. The significant increase in relative weight of kidney which was observed in males at 62.5 mg/kg bw/day after the administration period was not considered as test compound-related, since this change was within the historical background data of the test facility. No differences in liver and kidney weights were observed after the recovery period at any dose level.
In males of the 1000 mg/kg bw/day group, relative testis weight was significantly increased compared with the control group after the recovery period. However, this change was not considered as test item-related, since this was not observed after the administration period.
Based on the results of clinical chemistry examinations and organ weights, the test item may affect the liver. However, no changes were found at histopathological examinations in the liver. The test item did not cause any organic change. Changes observed in kidney weight and at histopathological examination suggest that the test item or its metabolites impaired lesions which occurred naturally. However, these changes in kidneys were reversible since they disappeared after the recovery period.
In females dosed 1000 mg/kg bw/day, absolute and relative weights of adrenals as well as relative weight of liver, kidney and uterus were significantly increased compared with the control group after the administration period. The increase in relative uterus weight was not considered test item-related, since this change was within the historical background data of the test facility. After the recovery period, the absolute, but not the relative, liver weight was significantly increased and no further changes were found.
GROSS PATHOLOGY
One male in the control group showed bilateral small size of testis and bilateral softness of testis after the administration period. One male in the 62.5 mg/kg bw/day showed lateral small size of testis and lateral small size of epididymis after the administration period. One male in the 1000 mg/kg bw/day showed bilateral small size of testis and bilateral small size of epididymis after the administration period. Due to the low incidence and lack of dose-response relationship, these changes were considered accidental.
No abnormalities were found in females after the administration period and in both sexes after the recovery period.
HISTOPATHOLOGY
After the administration period, one male in the control group showed slight cellular infiltration in the heart. One male in the control groups showed slight extramedullary haematopoiesis in the spleen. Slight bilateral hyaline droplet in renal tubule was observed in all males at 1000 mg/kg bw/day and 4 males at 250 mg/kg bw/day. Changes at 1000 mg/kg bw/day were statistically significant and dose-dependent. Slight bilateral basophilic change in renal tubules was observed in one male at 250 mg/kg bw/day. One male in the control group showed lateral cyst in kidney. Atrophy of the seminiferous tubule was observed in one male each at 62.5 and 1000 mg/kg bw/day. These animals showed also small size or softness of testis at gross pathology. One animal in the control, 62.5 and 1000 mg/kg bw/day group, respectively, showed slight cell debris in the lumen of epididymis. These animals showed also small size or softness of epididymis at gross pathology. Cell infiltration in the ventral prostate was observed in one male of the 1000 mg/kg bw/day group. All these changes except for slight bilateral hyaline droplet in the renal tubule at 250 and 1000 mg/kg bw/day were considered accidental, since they are usually observed in untreated animals and the incidence was not statistically significant. Hyaline droplet formation was likely related to alpha2µ-globulin accumulation, which is an effect specific for male rats and not relevant for humans.
After the recovery period, two males in the 1000 mg/kg bw/day group and one male in the control group showed bilateral/lateral basophilic change in the renal tubules. One male in the control group showed lateral cyst in the kidney. These changes were considered accidental, since they are usually observed in untreated animals and the incidence was not statistically significant.
One female of the control and 1000 mg/kg bw/day groups, respectively, showed slight lateral retinal dysplasia in the eyeball. This change was not considered test item-related, since it was also observed in control group and the incidence was not statistically significant.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 250 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: non-adverse/reversible overall effects
- Dose descriptor:
- LOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1. General clinical signs (salivation)
Administration period |
Recovery period |
|
Dose level (mg/kg bw/day) |
No. of animals with transient salivation/No. of animals examined |
No. of animals with transient salivation/No. of animals examined |
males |
||
Control |
0/12 |
0/6 |
62.5 |
0/12 |
0/6 |
250 |
0/12 |
0/6 |
1000 |
11/12 |
0/6 |
females |
||
Control |
0/12 |
0/5 |
62.5 |
0/12 |
- |
250 |
0/12 |
- |
1000 |
9/10 |
0/5 |
Table 2. Water consumption (g/day) during administration period (males, mean ±SD)
Dose level (mg/kg bw/day) |
||||
Control |
62.5 |
250 |
1000 |
|
males |
||||
Days of administration |
||||
2 |
33 ± 10 |
33 ± 4 |
33 ± 14 |
31 ± 5 |
5 |
34 ± 5 |
33 ± 5 |
32 ± 6 |
37 ± 5 |
9 |
37 ± 9 |
35 ± 6 |
32 ± 5 |
38 ± 5 |
12 |
37 ± 5 |
30 ± 6* |
36 ± 6 |
39 ± 5 |
* p < 0.05 by Dunnett’s test
Table 3. Urinary volume (mL) after administration period (males, mean ± SD)
Dose level (mg/kg bw/day) |
Day 22 of administration |
Day 12 of recovery |
Control |
8.7 ± 2.1 |
13.4 ± 3.9 |
62.5 |
15.5 ± 14.6 |
17.0 ± 7.0 |
250 |
16.1 ± 10.3 |
13.1 ± 6.0 |
1000 |
16.3 ± 4.9* |
15.4 ± 5.6 |
* p < 0.05 by Steel’s test
Table 4. Haematological and clinical chemistry findings (males, mean ± SD)
Parameter |
Dose level (mg/kg bw/day) |
|||
Control |
62.5 |
250 |
1000 |
|
males (administration period) |
||||
MCHC (g/dL) |
35.7 ± 0.3 |
36.0 ± 0.6 |
36.1 ± 0.6 |
36.1 ± 0.6 |
WBC (1E02/µL) |
68.3 ± 9.8 |
63.2 ± 13.6 |
65.2 ± 11.4 |
65.1 ± 24.3 |
Basophil (%) |
0.0 ± 0.0 |
0.0 ± 0.0 |
0.0 ± 0.0 |
0.0 ± 0.0 |
ALT (IU/L) |
25.5 ± 1.1 |
28.4 ± 3.9 |
35.6 ± 16.2 |
44.3 ± 17.6*** |
Gamma-GT |
0.61 ± 0.08 |
0.51 ± 0.11 |
0.65 ± 0.17 |
1.18 ± 0.33*** |
Total protein |
5.59 ± 0.22 |
5.48 ± 0.18 |
5.55 ± 0.15 |
6.25 ± 0.28** |
Glucose (mg/dL) |
107.9 ± 7.5 |
112.1 ± 9.2 |
103.2 ± 6.7 |
97.9 ± 10.1 |
Total cholesterol (mg/dL) |
45.1 ± 5.9 |
60.8 ± 8.4* |
60.5 ± 9.3* |
81.2 ± 12.6* |
Cl (mEq/L) |
108.6 ± 1.0 |
108.2 ± 1.0 |
107.2 ± 1.1* |
105.7 ± 0.5** |
Ca (mg/dL) |
9.6 ± 0.2 |
9.5 ± 0.2 |
9.5 ± 0.2 |
10.0 ± 0.2** |
males (recovery period) |
||||
MCHC (g/dL) |
36.4 ± 0.2 |
36.1 ± 0.4 |
35.9 ± 0.3* |
35.8 ± 0.3** |
WBC (1E02/µL) |
79.0 ± 22.2 |
52.1 ± 14.3* |
56.7 ± 18.3 |
50.2 ± 6.4* |
Basophil (%) |
0.1 ± 0.1 |
0.0 ± 0.0* |
0.0 ± 0.0* |
0.0 ± 0.0* |
ALT (IU/L) |
29.5 ± 6.2 |
27.6 ± 2.9 |
30.7 ± 6.4 |
39.6 ± 8.8* |
Gamma-GT |
0.44 ± 0.11 |
0.41 ± 0.06 |
0.43 ± 0.06 |
0.47 ± 0.12 |
Total protein |
5.64 ± 0.13 |
5.65 ± 0.33 |
5.62 ± 0.19 |
5.87 ± 0.47 |
Glucose (mg/dL) |
116.1 ± 7.6 |
109.9 ± 8.2 |
103.3 ± 8.8* |
109.5 ± 9.4 |
Total cholesterol (mg/dL) |
45.3 ± 6.3 |
51.6 ± 15.4 |
52.8 ± 10.4 |
73.1 ± 13.5** |
Cl (mEq/L) |
107.5 ± 1.1 |
108.0 ± 1.4 |
108.7 ± 1.3 |
106.8 ± 1.1 |
Ca (mg/dL) |
9.5 ± 0.4 |
9.4 ± 0.2 |
9.6 ± 0.2 |
9.7 ± 0.2 |
* p < 0.05 by Dunnett’s test
** p < 0.01 by Dunnett’s test
*** p < 0.05 by Steel’s test
Table 5. Haematological and clinical chemistry findings (females, mean ± SD)
Parameter |
Dose level (mg/kg bw/day) |
|||
Control |
62.5 |
250 |
1000 |
|
females (administration period) |
||||
Reticulocytes (%) |
2.76 ± 0.19 |
2.81 ± 0.28 |
2.71 ± 0.47 |
3.48 ± 0.48* |
Monocytes (%) |
1.7 ± 0.3 |
2.1 ± 0.7 |
2.5 ± 0.9 |
2.7 ± 0.4* |
Glucose (mg/dL) |
119.2 ± 10.6 |
110.1 ± 2.7 |
110.2 ± 9.0 |
105.9 ± 7.2* |
females (recovery period) |
||||
Reticulocytes (%) |
2.50 ± 0.67 |
- |
- |
2.23 ± 0.49 |
Monocytes (%) |
3.8 ± 1.2 |
- |
- |
3.1 ± 1.0 |
Glucose (mg/dL) |
118.3. ± 9.2 |
- |
- |
120.5 ± 8.3 |
* p < 0.05 by Dunnett’s test
Table 6. Organ weights (males , mean ± SD)
Organ |
absolute/relative weight |
Dose level (mg/kg bw/day) |
|||
Control |
62.5 |
250 |
1000 |
||
males (administration period) |
|||||
Liver |
g |
11.00 ± 0.32 |
10.95 ± 0.98 |
11.65 ± 0.57 |
15.18 ± 0.94** |
g% |
2.59 ± 0.08 |
2.64 ± 0.18 |
2.81 ± 0.13* |
3.82 ± 0.13** |
|
Kidney |
g |
2.75 ± 0.16 |
2.99 ± 0.31 |
2.92 ± 0.14 |
3.14 ± 0.20* |
g% |
0.65 ± 0.03 |
0.72 ± 0.07* |
0.70 ± 0.03 |
0.79 ± 0.04** |
|
Testes |
g |
2.85 ± 0.81 |
3.06 ± 0.47 |
3.16 ± 0.35 |
2.79 ± 0.98 |
g% |
0.67 ± 0.19 |
0.75 ± 0.16 |
0.76 ± 0.08 |
0.70 ± 0.25 |
|
males (recovery period) |
|||||
Liver |
g |
11.16 ± 1.42 |
10.97 ± 0.38 |
11.55 ± 0.97 |
12.25 ± 1.52 |
g% |
2.50 ± 0.26 |
2.49 ± 0.07 |
2.57 ± 0.10 |
2.83 ± 0.17 |
|
Kidney |
g |
3.04 ± 0.18 |
302 ± 0.25 |
2.96 ± 0.38 |
3.15 ± 0.22 |
g% |
0.68 ± 0.01 |
0.69 ± 0.05 |
0.66 ± 0.08 |
0.73 ± 0.05 |
|
Testes |
g |
3.05 ± 0.15 |
3.06 ± 0.18 |
3.23 ± 0.25 |
3.40 ± 0.46 |
g% |
0.68 ± 0.04 |
0.69 ± 0.04 |
0.72 ± 0.08 |
0.79 ± 0.09* |
* p < 0.05 by Dunnett’s test
** p < 0.01 by Dunnett’s test
Table 7. Organ weights (females, mean ± SD)
Organ |
absolute/relative weight |
Dose level (mg/kg bw/day) |
|||
Control |
62.5 |
250 |
1000 |
||
females (administration period) |
|||||
Liver |
g |
7.58 ± 0.60 |
7.84 ± 0.47 |
7.77 ± 0.48 |
8.29 ± 0.88 |
g% |
2.23 ± 0.19 |
2.75 ± 0.14 |
2.71 ± 0.12 |
3.02 ± 0.28* |
|
Kidney |
g |
1.83 ± 0.11 |
1.87 ± 0.09 |
1.95 ± 0.08 |
2.04 ± 0.25 |
g% |
0.64 ± 0.04 |
0.66 ± 0.03 |
0.68 ± 0.03 |
0.74 ± 0.09* |
|
Adrenals |
g |
65.3 ± 5.6 |
75.3 ± 8.7 |
74.7 ± 6.5 |
84.1 ± 8.5** |
g% |
22.7 ± 2.6 |
26.5 ± 3.5 |
26.1 ± 2.7 |
30.6 ± 2.4** |
|
Uterus |
g |
499 ± 69 |
542 ± 87 |
568 ± 148 |
665 ± 108 |
g% |
173 ± 23 |
190 ± 33 |
199 ± 54 |
243 ± 38* |
|
females (recovery period) |
|||||
Liver |
g |
7.41 ± 0.18 |
- |
- |
7.86 ± 0.37*** |
g% |
2.51 ± 0.07 |
- |
- |
2.69 ± 0.23 |
|
Kidney |
g |
1.94 ± 0.12 |
- |
- |
1.92 ± 0.18 |
g% |
0.66 ± 0.04 |
- |
- |
0.66 ± 0.06 |
|
Adrenals |
g |
78.2 ± 6.5 |
- |
- |
80.5 ± 10.0 |
g% |
26.5 ± 2.3 |
- |
- |
27.7 ± 4.5 |
|
Uterus |
g |
581 ± 165 |
- |
- |
595 ± 109 |
g% |
196 ± 56 |
- |
- |
203 ± 36 |
* p < 0.05 by Dunnett’s test
** p < 0.01 by Dunnett’s test
*** p < 0.05 by Student’s t-test
Table 8. Gross necropsy findings after administration period (males)
Finding |
Dose level (mg/kg bw/day) |
|||
Control |
62.5 |
250 |
1000 |
|
males (No. with findings/No. of animals examined) |
||||
Testis, small in size, bilateral |
1/6 |
0/6 |
0/6 |
1/6 |
Testis, small in size, lateral |
0/6 |
1/6 |
0/6 |
0/6 |
Testis, softness, bilateral |
1/6 |
0/6 |
0/6 |
0/6 |
Epididymis, small in size, bilateral |
0/6 |
0/6 |
0/6 |
1/6 |
Epididymis, small in size, lateral |
0/6 |
1/6 |
0/6 |
0/6 |
Table 9. Summary of histopathological findings after administration (males and females) and recovery period (males)
Finding |
Dose level (mg/kg bw/day) |
|||
Control |
62.5 |
250 |
1000 |
|
males after administration period (No. with findings/No. of animals examined) |
||||
Heart |
||||
cellular infiltration, slight |
1/6 |
- |
- |
0/6 |
Spleen |
||||
extramedullary haematopoiesis, slight |
1/6 |
- |
- |
0/6 |
Kidney |
||||
Hyaline droplet, renal tubule, bilateral, slight |
0/6 |
0/6 |
4/6 |
6/6* |
Basophilic change, renal tubule, bilateral, slight |
0/6 |
0/6 |
1/6 |
0/6 |
Cyst, lateral, slight |
1/6 |
0/6 |
0/6 |
0/6 |
Testis |
||||
Atrophy, seminiferous tubule, bi-/lateral, marked |
1/6 |
1/1 |
- |
1/6 |
Epididymis |
||||
Atrophy, bi-/lateral, slight |
1/6 |
0/1 |
- |
1/6 |
Atrophy, bi-/lateral, moderate |
0/6 |
1/1 |
- |
0/6 |
Cell debris, lumen, bi-/lateral, mild |
0/6 |
1/1 |
- |
0/6 |
Cell debris, lumen, bi-/lateral, marked |
1/6 |
0/1 |
- |
1/6 |
Ventral prostate |
||||
cellular infiltration, slight |
0/6 |
- |
- |
1/6 |
males after recovery period (No. with findings/No. of animals examined) |
||||
Kidney |
||||
Basophilic change, renal tubule, bilateral, slight |
1/6 |
0/6 |
0/6 |
2/6 |
Cyst, lateral, slight |
1/6 |
0/6 |
0/6 |
0/6 |
females after administration period (No. with findings/No. of animals examined) |
||||
Eyeball |
||||
retinal dysplasia, lateral, slight |
1/5 |
- |
- |
1/5 |
* p < 0.01 by Steel’s test (compared to control)
* p < 0.01 by Cochran-Armitage test (dose-response)
Applicant's summary and conclusion
- Conclusions:
- A GLP-compliant Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test (OECD 422) was conducted with methylcyclohexane. Groups of 12 male and 10 female rats per dose were given methylcyclohexane by oral gavage at 62.5, 250 and 1000 mg/kg bw/day, daily for 28 days. Concurrent male and female vehicle (corn oil) control groups were included. Satellite control and treatment groups were included for a 14-day recovery period. These groups comprised 6/12 males in the control and all dose groups, and 5/10 females in the control and high-dose groups, respectively.
At 1000 mg/kg bw/day, the observed effects in males included increased transient salivation after dosing, slight decrease in MCHC and WBC (only after recovery period), increased ALT, gamma-GT, total cholesterol and Ca values, decreased Cl values (all reversible except for ALT and total cholesterol), increased absolute and relative liver and kidney weights (reversible), increased relative testes weight (only after recovery period) and slight bilateral hyaline droplet in the renal tubules (reversible; alpha-2-microglubin-related and thus not relevant for humans). In females dosed 1000 mg/kg bw/day, the observed effects comprised increased transient salivation after dosing, increased reticulocytes and monocytes values (reversible), decreased glucose (reversible), increased absolute and relative adrenals and relative kidney weights (reversible) as well as increased relative liver weight (non-reversible).
In males of the 250 mg/kg bw/day group the observed effects were limited to a slight decrease in MCHC and WBC (only after recovery period), reversible increase in total cholesterol, slight reversible decrease in Cl and slight reversible bilateral hyaline droplet in the renal tubules (alpha-2-microglubin-related and thus not relevant for humans). No effects were observed in females dosed 250 mg/kg bw/day.
Based on the effects observed at 1000 mg/kg bw/day, in particular transient salivation after dosing (males and females) and non-reversible increases in ALT and total cholesterol values in males and relative liver weight in females, the oral NOAEL for males and female rats was 250 mg/kg bw/day.
Based on the study results, methylcyclohexane does not fulfil the classification criteria for toxicity after repeated exposure according to Regulation (EC) No 1272/2008 and Directive 67/548/EEC.
CLP: not classified
DSD: not classified
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.